Press "Enter" to skip to content

The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular’s Glaucoma Trial Fails – Benzinga

admin 0

The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular’s Glaucoma Trial Fails  Benzinga

Here’s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 20) …

“ovarian cancer” – Google News

(Visited 4 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *